MIPLA

From PsychonautWiki
Jump to: navigation, search
MIPLA
MiPLA-skeletal-structure.svg
Chemical Nomenclature
Common names MiPLA, Lamide
Substitutive name Methylisopropyllysergamide
Systematic name (6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 50 µg
Light 100 - 150 µg
Common 150 - 200 µg
Strong 200 - 250 µg
Heavy 300 µg +
Duration
Total 4 - 6 hours
Onset 20 - 40 minutes
Come up 45 - 90 minutes
Peak 1 - 2 hours
Offset 1 - 2 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
Lithium
Tramadol


N-Methyl-N-isopropyllysergamide (also known as methylisopropyllysergamide, Lamide and MIPLA) is a lesser-known novel psychedelic substance of the lysergamide class. MIPLA is closely related to LSD and has a similar mechanism of action, working primarily by binding to the serotonin-2A receptor in the brain.[citation needed]

MIPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for LSD. It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University. MIPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".[1][2] According to Shulgin, human subjects administered MIPLA at doses of 180–300 μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.[3]

User reports describe the effects of MIPLA as similar to those of LSD, with some notable differences. MIPLA has been described as being more mentally and physically oriented but with a less introspective headspace accompanied by subtle visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than LSD and other lysergamides.

Very little data exists about the pharmacological properties, metabolism, and toxicity of MIPLA. It is highly advised to use harm reduction practices when using this substance.

Chemistry

The chemical name of MIPLA is methylisopropyllysergamide. MIPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is LSD, lysergic acid diethylamide.

MIPLA is a structural isomer of LSD. Like LSD, the chemical structure of MIPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MIPLA is substituted with a methyl and isopropyl group.

MIPLA is a chiral compound with two stereocenters at R5 and R8. The differences in psychoactivity between the stereoisomers have not yet been investigated.

Pharmacology

As with its structurally related lysergamides, MIPLA principally acts as a 5-HT2A partial agonist, through which it exerts its psychedelic effects. However, the role of these interactions and how they result in the psychedelic experience is unclear.

Owing to similarities in chemical structure, MIPLA and LSD have highly similar binding profiles at monoamine receptors (i.e. serotonin, dopamine, and norepinephrine).[citation needed]

One study found MIPLA to fully substitute for LSD in rats, with about half the potency of the training drug.[citation needed]

Subjective effects

Metacogghjgjvghnition.png
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding it.

MIPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical effects
Child.svg

Visual effects
Eye.svg

Transpersonal effects
Infinity4.svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational MIPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MIPLA is a research chemical with very little history of human usage.

The current body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

However, as is the case for LSD, it is possible that MIPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.

It is strongly recommended that one uses harm reduction practices when using this substance.

Overdose

The LD50 of MIPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and (more rarely) seizures. Medical attention is usually only needed in the case of severe psychotic episodes or “fake acid” (a counterfeit substance such as 25x-NBOMe or DOx). Administration of benzodiazepines or antipsychotics can help to relieve the negative psychological effects of MIPLA.

Dependence and abuse potential

Like other serotonergic psychedelics, MIPLA is believed to have a low potential for abuse and dependence. This is owing to its structural and pharmacological similarities with LSD. See this section to learn more about the dependence and abuse potential of LSD. It should be noted that all claims related to the abuse potential of MIPLA are preliminary and based on anecdotal (as opposed to clinical) evidence and should be interpreted with caution.

As with LSD, tolerance to the effects of MIPLA forms almost immediately after ingestion. After that, it is assumed to take about 5-7 days for the tolerance to be reduced to half and 14 days to be return to baseline (in the absence of further consumption).

Due to its activity at the 5-HT2A receptor, MIPLA produces cross-tolerance with all psychedelics, meaning that after the consumption of MIPLA all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The following lists some known dangerous combinations, but may not include all of them. A combination that appears to be safe in low doses can still increase the risk of injury or death. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from Tripsit.

  • Lithium - Individuals who take lithium for bipolar disorder or other psychiatric conditions should not take MIPLA. There are numerous anecdotal reports of individuals experiencing seizures and/or psychosis from the combination of LSD and lithium.[4][5][6][7] Due to MIPLA's chemical similarity to LSD, it is assumed to carry a similar risk.
  • Tramadol - Tramadol lowers the seizure threshold[8] and psychedelics may act as triggers for seizures, particularly in predisposed individuals.[citation needed]
  • Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.[citation needed]

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

MIPLA is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area throughout most of the world, meaning that it might not be specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Austria: MIPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.[citation needed]
  • United States: MIPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.

See also

External links

Discussion

Literature

References

  1. https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf
  2. https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf
  3. Halberstadt, A.L., Klein, L.M., Chatha, M. et al. Psychopharmacology (2018). http://dx.doi.org/10.1007/s00213-018-5055-9
  4. https://erowid.org/chemicals/lsd/lsd_interactions.shtml | LSD Interactions by Erowid
  5. Wanderli. "A Nice Little Trip to the Hospital: An Experience with Lithium & LSD (ID 83935)". Erowid.org. Oct 3, 2010.
  6. MissDja1a. "Having a Seizure and Passing Out: An Experience with Lithium & LSD (ID 75153)". Erowid.org. Dec 16, 2008.
  7. Reddit account of seizure on LSD + Lithium | https://www.reddit.com/r/Psychonaut/comments/17uspp/please_read_a_cautionary_tale_concerning_lsd/
  8. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089